Tvardi Therapeutics (LTS:0HTC) Scaled Net Operating Assets: -0.32 (As of Mar. 2026)


What is Tvardi Therapeutics Scaled Net Operating Assets?

Tvardi Therapeutics LTS:0HTC 12 Scaled Net Operating Assets is -0.32 as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tvardi Therapeutics's operating assets for the quarter that ended in Mar. 2026 was £0.63 Mil. Tvardi Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was £8.35 Mil. Tvardi Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was £23.96 Mil. Therefore, Tvardi Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.32.

Tvardi Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Scaled Net Operating Assets Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
-1.96 -1.81 -3.42 -0.26

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1.18 0.29 -0.19 -0.25 -0.32

LTS:0HTC vs HOWL, TPST, XCUR: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Scaled Net Operating Assets falls into.


Tvardi Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tvardi Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(0.943-8.162)/27.842
=-0.26

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=23.959 - 23.016
=0.943

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.312 - 0.063 - 0.087
=8.162

Tvardi Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(0.627-8.353)/23.959
=-0.32

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=19.363 - 18.736
=0.627

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.484 - 0.041 - 0.09
=8.353

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.32 mean?
Tvardi Therapeutics (LTS:0HTC) has a Scaled Net Operating Assets of -0.32 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Scaled Net Operating Assets too high?
Tvardi Therapeutics' current Scaled Net Operating Assets is -0.32. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Scaled Net Operating Assets compare to HOWL and TPST?
Tvardi Therapeutics' Scaled Net Operating Assets of -0.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Scaled Net Operating Assets is -0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Scaled Net Operating Assets of -0.32. The current Scaled Net Operating Assets is -0.32. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Scaled Net Operating Assets is -0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.